Coastlands Capital LP purchased $33K of ADIL (indirect holdings)
Coastlands Capital LP purchased 11,753 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at an average of $2.78 ($2.70–$2.79) across 2 trades over 2026-07-09 to 2026-07-10.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market purchase window (2026-07-09 to 2026-07-10), share count (11,753), and price range ($2.70 to $2.79), which may slightly influence sentiment but does not provide new operating or regulatory information.
Market read
Traders may note incremental accumulation by a large owner, but the disclosed value is modest and lacks accompanying fundamental catalysts.
What to watch
The article does not indicate whether the 10b5-1 plan exists (it says no pre-arranged plan), but it also provides no context on prior holdings changes or broader corporate catalysts.
Background
This is an SEC Form 4 insider transaction disclosure for ADIAL PHARMACEUTICALS, INC. (ADIL), reported by Coastlands Capital LP as a 10% owner via indirect holdings.
Ticker impact
Coastlands Capital LP, a 10% owner, bought 11,753 ADIL shares indirectly in open-market trades at $2.70 to $2.79 (Form 4).
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.
The filing is a primary-source Form 4 showing the transaction details, but the dollar value (~$32.6K) and indirect nature reduce expected market-moving significance.
Market effects
No clear sector read-through from a small, indirect owner purchase.
None indicated.
None indicated.
Counterpoint
Owner purchases on Form 4 can reflect routine portfolio rebalancing or indirect arrangements, not a new bullish thesis.
Key entities
- issuerADIL
Adial Pharmaceuticals, Inc., the company whose shares were purchased.
- 10% ownerCoastlands Capital LP
Reported the open-market purchase of ADIL shares via indirect holdings.